⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
EXEL News
Exelixis Inc
Metastatic Prostate Cancer Market Set for Robust Growth Through 2036, Driven by The Emergence of PARP Inhibitors and PSMA-targeted Radioligand Therapies | DelveInsight
globenewswire.com
NVS
TLX
PFE
EXEL
LLY
XNCR
BTE
ORIC
MRK
ABBV
BMY
AZN
AMGN
Reco Expands Executive Team and Global Footprint to Accelerate Leadership in Enterprise AI Agent Security
prnewswire.com
EXEL
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX ® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
businesswire.com
EXEL
Form 8-K
sec.gov
EXEL
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in June
businesswire.com
EXEL
Halia Therapeutics Appoints Gary Sabin as Executive Chairman and Adds Three Independent Directors to Board
prnewswire.com
JNJ
EXEL
EXR
CTRE
Global Colorectal Cancer Diagnostics and Therapeutics Market Anticipates Impressive Growth Trajectory at a CAGR of ~9% by 2034 | DelveInsight
globenewswire.com
AGEN
EXEL
ABBV
BMY
MRK
LYEL
PFE
BNTX
NVDA
IBM
GEHC
ABT
QGEN
TMO
DHR
MYGN
ILMN
EXAS
INV
Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May
businesswire.com
EXEL
PARP Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
globenewswire.com
AZN
MRK
JNJ
PFE
ABBV
GSK
ALLR
SNY
CURI
ORIC
EXEL
ABSI
LLY
TLX
FPH
BMY
SNX
XNCR
ZENA
ARVN
MGNX
DASH
VERU
GILD
EVGN
GEN
AMGN
MIR
RXRX
BG
MTX
BIO
Thyroid Cancer (TC) Market View Report 2026: Ipsen/Exelixis, Ono Pharmaceutical, and Novartis Dominate the Treatment Landscape
globenewswire.com
EXEL
NVS